Latest Breaking News On - Pfizer worldwide research development - Page 1 : comparemela.com

CellCentric Receives $25M Strategic Investment from Pfizer

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United kingdomAstrid ruefli brassePfizer global product developmentDevelopment headUniversity of cambridgePfizer worldwide research developmentUnited kingdom basedPfizer igniteProfessor azim suraniVice presidentTumour biologyPfizer worldwide researchScientific advisory boardMultiple myeloma

Acrivon Therapeutics (ACRV) Appoints Charles Baum to its Board

Acrivon Therapeutics (ACRV) Appoints Charles Baum to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCharles chuck baumPeter blume jensenWashington university school of medicinePfizer worldwide research developmentAcrivon therapeutics incPharmaceuticals incBioinnovation centerNational institutes of healthAmerican cancer societyStanford universityAcrivon therapeuticsMirati therapeuticsWorldwide researchOdyssey therapeuticsWashington university school

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M D , Ph D , a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

22.06.2023 - Dr. Baum comes with more than 30 years of biopharma industry leadership experience, including at Mirati Therapeutics, Pfizer and Schering-Plough WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) - Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon . Seite 1

United statesPeter blume jensenBioinnovation centerPharmaceuticals incAmerican cancer societyWashington university school of medicineNational institutes of healthStanford universityPfizer worldwide research developmentMirati therapeuticsWorldwide researchOdyssey therapeuticsWashington university schoolNational institutesAcrivon therapeutics

Poseida Therapeutics Appoints Charles M Baum, M D , Ph D , to Board of Directors

Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors - read this article along with other careers information, tips and advice on BioSpace

United statesMark gergenDavid hirschCharlesm baumHead of researchHead of oncology developmentPoseida therapeutics incPrnewswire poseida therapeutics incBioinnovation centerAmerican cancer societyNational institutes of healthAcquisition corpWashington university school of medicineExchange commissionPfizer worldwide research developmentBoard of directors at mirati therapeutics inc

Poseida Therapeutics (PSTX) Appoints Charles M Baum to its Board

Poseida Therapeutics (PSTX) Appoints Charles M Baum to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMark gergenDavid hirschCharlesm baumHead of researchAcquisition corpHead of oncology developmentNational institutes of healthWashington university school of medicinePoseida therapeutics incPfizer worldwide research developmentBioinnovation centerBoard of directors at mirati therapeutics incBiotherapeutic clinical researchStanford universityAmerican cancer society